The Italian Journal of Neurological Sciences

, Volume 8, Issue 6, pp 561–566 | Cite as

A multiparametric index of platelet in vitro aggregation in cerebrovascular disease

  • Gazzaniga P. P. 
  • Ferroni P. 
  • Mina C. 
  • Pulcinelli F. M. 
  • Rizzo P. A. 
Original Article

Abstract

148 patients with various forms of cerebrovascular disease (CVD) were studied by means of a multiparametric analysis ofin vitro platelet aggregation, based on the following six parameters: ADP and epinephrine primary and secondary aggregation thresholds and percent maximum aggregation induced by optimal concentrations of ADP and epinephrine. These patients were assigned to four study groups, according to clinical diagnosis supported by CT scan, of transient ischemic attack and reversible neurological deficit (TIA-RIND), or completed stroke, in the presence or absence respectively of antiplatelet medical treatment at the time of the study. A statistically significant increase of thein vitro platelet aggregation was found in 44.4% of the untreated TIA-RIND patients and in 33.9% of the untreated stroke patients. However this last group showed a higher percentage of very marked hyperaggregation. Differences between the two treated study groups and controls were not signicant. No difference was found in collagen-and ristocetin-induced aggregation between the patient groups and the controls.

Key-Words

Cerebrovascular disease platelet aggregation platelet hyperaggregation transient ischemic attacks stroke 

Sommario

148 pazienti con varie forme di malattia cerebrovascolare, sono stati studiati con analisi multiparametriche dell'aggregazione piastrinica in vitro sulla base dei seguenti sei parametri: le soglie di aggregazione primaria e secondaria e l'aggregazione massima percentuale indotta da ADP ed Epinefrina. Questi pazienti sono stati suddivisi in 4 gruppi di studio in accordo con la diagnosi clinica confortata dai dati della TAC e cioè: TIA, RIND, o rammollimento in presenza o in assenza rispettivamente di un trattamento antiaggregante nel momento dello studio. È stato trovato un aumento statisticamente significativo dell'aggregazione in vitro delle piastrine nel 44.4% dei casi TIA, RIND non trattati e nel 33,9% dei casi di rammollimento non trattati. Quest'ultimo gruppo, però, ha dimostrato una più alta percentuale di iperaggregazione molto marcata. Le differenze tra i 2 gruppi di studio trattati con antiaggreganti e i controlli non erano significative. Inoltre nessuna differenza è stata riscontrata tra i gruppi e i controlli nell'aggregazione indotta da collageno e ristocetina.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Bousser M.G., Eschwege E., Haguenau M., et al.:“AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14: 5–14, 1983.PubMedGoogle Scholar
  2. [2]
    Buren A., Ygge J.:Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attacks. Stroke 12: 578–580, 1981.PubMedGoogle Scholar
  3. [3]
    Dougherty J.H. Jr, Levy D.E., Weksler B.B.:Platedet activation in acute cerebral ischemia. Lancet 1: 821–824, 1977.PubMedGoogle Scholar
  4. [4]
    Ferroni P., Gazzaniga P.P., La Mancusa R., Mina C., Pulcinelli F.M., Rizzo P.A.:L'aggregazione piastrinica in vitro in pazienti cerebrovascolari e neoplastici. Proposta di un indice multiparametrico. G.I. Pat. Clin 1 (1): 39–44, 1986.Google Scholar
  5. [5]
    Gallus A.S.:Asptrin and other platelet-aggregation inhibiting drugs. Med. J. Aust. 142: 41–47, 1985.PubMedGoogle Scholar
  6. [6]
    Garde A., Samuelsson K., Fahlgren H., Hedberg E., Hjerne L.G., Ostman J.:Treatment after transient ischemic attacks: a comparison between anticoagulant drugs and inhibition of platelet aggregation. Stroke 14: 677–681, 1983.PubMedGoogle Scholar
  7. [7]
    Hansen P.E., Hansen J.H., Stenbjerg S.:Platelet aggregation in focal cerebral ischemia. A clinic study. Acta Neurol. Scandinav. 65: 212–218, 1982.Google Scholar
  8. [8]
    Herkovits E., Famulari A., Tamaroff L., et al.:Randomized trials of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischemic attacks. Lancet 1: 966–968, 1981.Google Scholar
  9. [9]
    Kobayashi I., Fujita T., Yamazaki H.:Platelet aggregability measured by screen filtration pressure method in cerebrovascular disease. Stroke 6: 406–409, 1976.Google Scholar
  10. [10]
    Lechner H., Ott E., Bertha G.:Therapeutical aspects of cerebrovascular disease. Eur. Neurol. 22 (suppl. 1): 74–77, 1983.PubMedGoogle Scholar
  11. [11]
    Millikan C.H., Bauer R.B., Goldschmidt J., et al:A classification and outline of cerebrovascular disease. Stroke 6: 564–616, 1975.Google Scholar
  12. [12]
    Norrving B., Olsson J.E., Nilsson B.:Prophylactic treatment in patients with transient cerebral ischemia: anticoagulant vs. antiplatelet drugs. (Abstr.) Thromb. Haemost. 50: 20, 1983.Google Scholar
  13. [13]
    Ramirez-Lassepas M.:Platelet inhibitors for TIAs. A review of prospective drug trial results. Postgraduate Medicine 75: 52–62, 1984.PubMedGoogle Scholar
  14. [14]
    Shinichiro U., Megumi T., Mikio O., et al:Platelet function tests in thrombotic cerebrovascular disorders. Stroke 14: 511–517, 1983.Google Scholar
  15. [15]
    Soelberg Sorensen P., Agerskov Andersen L., Gormsen J., et al:Prognostic value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with reversible cerebral ischemic attacks. Eur. Neurol. 22: 437–441, 1983.PubMedGoogle Scholar
  16. [16]
    Soelberg Sorensen P., Pedersen H., Marquardsen J., et al:Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 14: 15–22, 1983.Google Scholar

Copyright information

© Masson Italia Periodici 1987

Authors and Affiliations

  • Gazzaniga P. P. 
    • 1
  • Ferroni P. 
    • 1
  • Mina C. 
    • 2
  • Pulcinelli F. M. 
    • 1
  • Rizzo P. A. 
    • 2
  1. 1.Dipartimento di Medicina Sperimentale, Sezione di Fisiopatologia piastrinicaUniversità di RomaItaly
  2. 2.II Clinica NeurologicaUniversità di RomaRoma

Personalised recommendations